Wealth Enhancement Advisory Services’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
Other funds holding LAB
LFCM
Wealth Enhancement Advisory Services's LAB Position: Q3 2026 in Review
Wealth Enhancement Advisory Services sold out of Standard BioTools (LAB) in Q3 2026, closing a stake of 42,090 shares — an estimated $38.7K sold.
Wealth Enhancement Advisory Services first reported a position in LAB in Q3 2024 and held it in 7 quarters. The position peaked at $38.7K in Q2 2026. 104 funds tracked by Wall St. Rank hold LAB as of Q3 2026.
- Wealth Enhancement Advisory Services reported no remaining Standard BioTools position as of Q3 2026 after selling out during the quarter.
- Wealth Enhancement Advisory Services sold 42,090 Standard BioTools shares in Q3 2026, an estimated $38.7K.
- Wealth Enhancement Advisory Services first reported a position in Standard BioTools in Q3 2024 and held it in 7 quarters.
- Wealth Enhancement Advisory Services's Standard BioTools position peaked at $38.7K in Q2 2026.
- 104 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.
Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.